SCHEMBL4426193

SCHEMBL4426193

FC(F)(F)c1cnnc(N2CCNCC2)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADRB1 P08588 2/20 0.59
▸ ALDH1A1 P00352 2/20 0.46
▸ HTR2C P28335 2/20 0.46
▸ HTR3E A5X5Y0 1/20 0.46
▸ HTR3B O95264 1/20 0.46
▸ HTR1D P28221 1/20 0.46
▸ HTR3A P46098 1/20 0.46
▸ HTR3D Q70Z44 1/20 0.46
▸ HTR3C Q8WXA8 1/20 0.46
▸ SIGMAR1 Q99720 1/20 0.46
▸ MAPT P10636 1/20 0.45
▸ THRB P10828 1/20 0.45
▸ ADRB2 P07550 2/20 0.42
▸ NCF1 P14598 1/20 0.42
▸ TRPV1 Q8NER1 1/20 0.41
▸ CYP1A2 P05177 2/20 0.40
▸ CYP2C19 P33261 2/20 0.40
▸ CASP1 P29466 1/20 0.40
▸ CASP4 P49662 1/20 0.40
▸ CASP5 P51878 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31061384 1.00 ADRB1 (0.59) ADRB1ALDH1A1HTR2CHTR3EHTR3B
Tert-Butyl Formate SCHEMBL27648860 0.85 ADRB1 (0.48) ADRB1ALDH1A1HTR2CHTR3EHTR3B
SCHEMBL27426567 0.83 CCR6 (0.46) ADRB1MAPTTHRBTRPV1CYP1A2
SCHEMBL12968858 0.81 HRH4 (0.46) HTR3ATRPV1CYP1A2CYP2C19HRH4
SCHEMBL18254932 0.81 TRPV1 (0.43) ADRB1MAPTTRPV1CASP1CASP5
SCHEMBL24006880 0.77 TRPV1 (0.44) ALDH1A1MAPTTRPV1CASP1CASP4
SCHEMBL18252833 0.77 TRPV1 (0.44) TRPV1
SCHEMBL18790715 0.75 CHRNB2 (0.53) ADRB1ALDH1A1HTR2CHTR3EHTR3B
SCHEMBL210342 0.74 ADRB1 (1.00) ADRB1ALDH1A1HTR2CHTR3EHTR3B
SCHEMBL25431906 0.74 ADRB1 (0.59) ADRB1ALDH1A1HTR2CHTR3EHTR3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7605163-B2 Benzoyl-piperazine derivatives HOFFMANN-LA ROCHE INC. (US) 2009-10-20 — — US disclosed
US-20080119486-A1 BENZOYL-PIPERAZINE DERIVATIVES JOLIDON SYNESE 2008-05-22 — — US disclosed
US-7319099-B2 Such as 1-{3-fluoro-4-[4-(2-isopropoxy-5-methanesulfonyl benzoyl)-piperazin-1-yl]-phenyl}-ethanone for treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia, attention deficit disorders, or Alzheimer's disease HOFFMANN-LA ROCHE INC. (US) 2008-01-15 — — US disclosed
EP-1656361-B1 PIPERAZINE WITH OR-SUBSTITUTED PHENYL GROUP AND THEIR USE AS GLYT1 INHIBITORS HOFFMANN LA ROCHE (CH) 2008-01-02 — — EP disclosed
EP-1656361-A1 PIPERAZINE WITH OR-SUBSTITUTED PHENYL GROUP AND THEIR USE AS GLYT1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2006-05-17 — — EP disclosed
US-20050209241-A1 Benzoyl-piperazine derivatives HOFFMANN-LA ROCHE INC. 2005-09-22 — — US disclosed
WO-2005014563-A1 PIPERAZINE WITH OR-SUBSTITUTED PHENYL GROUP AND THEIR USE AS GLYT1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2005-02-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050209241-A1 Benzoyl-piperazine derivatives SLC1A2, SLC18A2, SLC6A7 ADRB1 630/4885ALDH1A1 1436/4885HTR2C 157/4885
US-20080119486-A1 BENZOYL-PIPERAZINE DERIVATIVES SLC1A2, SLC18A2, SLC6A7 ADRB1 630/4885ALDH1A1 1436/4885HTR2C 157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback